{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:52:30Z","timestamp":1770447150765,"version":"3.49.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,20]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Only a few F9 nonsense mutations are responsive to drug-induced readthrough due to specific translation and protein structural constraints. Reinsertion of the WT residue and gain-of-function effects account for functionally relevant readthrough.<\/jats:p>","DOI":"10.1182\/blood-2016-09-738641","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T01:55:20Z","timestamp":1487123720000},"page":"2303-2307","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-2694","authenticated-orcid":false,"given":"Alessio","family":"Branchini","sequence":"first","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Ferrarese","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Campioni","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Mari","sequence":"additional","affiliation":[{"name":"Centre for Haemostasis and Thrombosis, Haematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Pinotti","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"15","key":"2019111904161437400_B1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111904161437400_B2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111904161437400_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","article-title":"Sense from nonsense: therapies for premature stop codon diseases","volume":"18","author":"Bidou","year":"2012","journal-title":"Trends Mol Med"},{"key":"2019111904161437400_B4","first-page":"757","article-title":"Genetic disorders of coagulation","volume-title":"Oxford Textbook of Medicine","author":"Pollak","year":"2003"},{"key":"2019111904161437400_B5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"2019111904161437400_B6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1538-7836.2006.01915.x","article-title":"Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII","volume":"4","author":"Pinotti","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"39","key":"2019111904161437400_B7","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.0610878104","article-title":"A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin","volume":"104","author":"Yang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111904161437400_B8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/humu.22120","article-title":"Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations","volume":"33","author":"Pinotti","year":"2012","journal-title":"Hum Mutat"},{"issue":"10","key":"2019111904161437400_B9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.13443","article-title":"Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency","volume":"14","author":"Branchini","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111904161437400_B10","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2005-03-1307","article-title":"Aminoglycoside suppression of nonsense mutations in severe hemophilia","volume":"106","author":"James","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111904161437400_B11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1538-7836.2006.02057.x","article-title":"Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations","volume":"4","author":"Pinotti","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111904161437400_B12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"issue":"7","key":"2019111904161437400_B13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2019111904161437400_B14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"issue":"15","key":"2019111904161437400_B15","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1093\/nar\/gku663","article-title":"New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae","volume":"42","author":"Blanchet","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"9371","key":"2019111904161437400_B16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"2019111904161437400_B17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"issue":"5","key":"2019111904161437400_B18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00195805","article-title":"Recurrent nonsense mutations at arginine residues cause severe hemophilia B in unrelated hemophiliacs","volume":"84","author":"Koeberl","year":"1990","journal-title":"Hum Genet"},{"key":"2019111904161437400_B19"},{"issue":"19","key":"2019111904161437400_B20","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.febslet.2013.08.019","article-title":"Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity","volume":"587","author":"Branchini","year":"2013","journal-title":"FEBS Lett"},{"issue":"17","key":"2019111904161437400_B21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111904161437400_B22","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111904161437400_B23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111904161437400_B24","first-page":"831","article-title":"The rates of G:C-->T:A and G:C-->C:G transversions at CpG dinucleotides in the human factor IX gene","volume":"54","author":"Ketterling","year":"1994","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2019111904161437400_B25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0037-1615583","article-title":"Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India","volume":"94","author":"Jayandharan","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111904161437400_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0049-3848(92)90249-A","article-title":"Factor IX mutations: rapid, direct screening methods for 20 new families with hemophilia B","volume":"65","author":"Thompson","year":"1992","journal-title":"Thromb Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/16\/2303\/1399954\/blood738641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/16\/2303\/1399954\/blood738641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:44:46Z","timestamp":1692686686000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/16\/2303\/35926\/Specific-factor-IX-mRNA-and-protein-features-favor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,4,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-738641","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}